This week, Novartis AG informed the U.S. Food and Drug Administration and other regulatory agencies that a 59 year old patient suffering from multiple sclerosis passed away after beginning a treatment with the drug Gilenya (fingolimod), the first pill approved by the FDA to treat the neurological disease.

The drug, which was approved for use in the U.S. just last year, has already been given to more than 28,000 patients. However, due to recent events, the drug’s safety is now being called into question. While Gilenya’s role in the patient’s death remains unclear, it was still the first passing reported within 24 hours of starting treatment with the drug.

The drug’s maker, Novartis AG, had high hopes for Gilenya, projecting it would become the company’s next blockbuster product. After all, sales of the drug could provide a much-needed earnings boost for Novartis, especially considering the fact that patents on several of the company’s best selling drugs will soon expire.

Novartis has reportedly submitted details of the case to the FDA for review. The patient who died started treatment with Gilenya on November 22 and was monitored without incident for six hours after taking the first dose. With MS drugs, patients are often susceptible to a long list of potential adverse events and safety issues.

(Source: 12/13)


Frank M. Eidson P.A. has been tirelessly representing the rights of Central Florida victims since 1989.

$4.2 Million

Auto Accident

$2.3 Million

Workers Comp Case

$5.65 Million

Auto Accident

Free, No Obligation Case Review.

Fill out our contact form below for your free, no obligation case review.

  • This field is for validation purposes and should be left unchanged.

Help provide wounded servicemen and women with therapeutic outdoor adventures. Like our Facebook page and we'll contribute $1 to Wounded Warriors Outdoors.

Contact Our Orlando Attorney

If you have been injured in an accident, turn to Frank M. Eidson P.A. Whether your case is a simple collision or a complicated auto wrongful death case, contact personal injury lawyer Frank Eidson today to schedule your free consultation.